Key statistics
On Friday, Akari Therapeutics PLC (CLA:DUS) closed at 2.14, 25.88% above the 52 week low of 1.70 set on Oct 23, 2024.
52-week range
Open | 1.99 |
---|---|
High | 2.14 |
Low | 1.99 |
Bid | 2.00 |
Offer | 2.34 |
Previous close | 2.10 |
Average volume | 1.00 |
---|---|
Shares outstanding | 607.23k |
Free float | 485.78k |
P/E (TTM) | -- |
Market cap | 29.75m USD |
EPS (TTM) | -2.98 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 18:31 GMT.
More ▼
Announcements
- Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
- Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
- Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
- Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
- Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
More ▼